肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 1 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing
我们的研究表明，GADEKILL 具有潜在的抗神经母细胞瘤活性，支持其治疗用途，尤其是在 GD2 低表达的复发/难治性 R/R HR-NB 中。
Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.
Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1.
MEMBER ACCOUNT
登录成功会直接打开下一页。
